

OncoScan[®] FFPE Assay Kit peer-reviewed publications by cancer type or site

Bile Ducts/Cholangiocarcinoma

Arnold A., et al. [Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay](#). *Experimental and Molecular Pathology* **99**(2):344–353 (2015).

Bladder

Shapiro S. G., et al. [Canine urothelial carcinoma: genomically aberrant and comparatively relevant](#). *Chromosome Research* **23**(2):311–331 (2015).

Bambury R. M., et al. [DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors](#). *BMC Cancer* **15**:242 (2015).

Guancial E. A., et al. [FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder](#). *Cancer Medicine* **3**(4):835–844 (2014).

Togneri F. S., et al. [Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA](#). *European Journal of Human Genetics* (2016). doi:10.1038/ejhg.2015.281

Chekaluk Y., et al. [Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value](#). *PLoS ONE* **8**(4):e60927 (2013).

Riester M., et al. [Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma](#). *Clinical Cancer Research* **20**(7):1873–1883 (2014).

Blood/Haematologic

Schoumans, J., et al. [Guidelines for Genomic Array Analysis in Acquired Haematological Neoplastic Disorders](#). *Genes, Chromosomes and Cancer* **55**(5):480–491 (2016).

Bone/Osteosarcoma

Jahromi M. S., Jones K. B., Schiffman J. D. [Copy Number Alterations and Methylation in Ewing's Sarcoma](#). *Sarcoma* **2011**:362173 (2011).

Jahromi M. S., et al. [Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma](#). *Cancer Genetics* **205**:391e404 (2012).

Jour G., et al. [The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study](#). *The Journal of Pathology: Clinical Research* **2**(1):9–20 (2016).

Ribi S., et al. [TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome](#). *Oncotarget* **6**(10):7727–7740 (2015).

Brain/Astrocytoma/Gliomas

Ho, C-Y, et al. [A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation](#). *Acta Neuropathologica* **130**(4):575–585 (2015).

van den Bent M. J., et al. [Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas](#). *Neuro Oncology* **17**(7): 935–941 (2015).

- Ruland V., et al. [Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis](#). *Genes, Chromosomes and Cancer* **53**(5):373–380 (2014).
- Xu J., et al. [Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia](#). *Frontiers in Oncology* **5**:191 (2015).
- Cohen A., et al. [DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status](#) *Acta Neuropathologica Communications* **3**:34 (2015).
- Xu M., et al. [Extensive therapies for extraneural metastases from glioblastoma, as confirmed with the OncoScan assay](#). *World Neurosurgery* **90**:698.e7–698.e11 (2016).
- Lovvorn III, H. N., et al. [Genetic and chromosomal alterations in Kenyan Wilms Tumor](#). *Genes, Chromosomes and Cancer* **54**(11):702–715 (2015).
- Marco G., et al. [Genome-Wide DNA Copy Number Analysis of Desmoplastic Infantile Astrocytomas and Desmoplastic Infantile Gangliogliomas](#). *Journal of Neuropathology & Experimental Neurology* **72**(9):807–815 (2013).
- Japp A. S., et al. [High-Resolution Genomic Analysis Does Not Qualify Atypical Plexus Papilloma as a Separate Entity Among Choroid Plexus Tumors](#). *Journal of Neuropathology & Experimental Neurology* **7**(2):110–120 (2015).
- Schittenhelm J., [Integrated Diagnostic Approach for Adult Oligodendroglioma and Oligoastrocytoma](#) *Brain Disorders & Therapy* **4**(4):187 (2015).
- Merino D. M., et al. [Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups](#). *Clinical Cancer Research* **21**(1):184–192 (2015).
- Gessi M., et al. [Molecular characterization of disseminated pilocytic astrocytomas](#). *Neuropathology and Applied Neurobiology* **42**(3):273–278 (2016).
- Goschzik T., et al. [Molecular stratification of medulloblastoma: Comparison of histological and genetic methods to detect Wnt activated tumors](#). *Neuropathology and Applied Neurobiology* **41**(2):135–144 (2015).
- Singh N., et al. [Multiomics approach showing genome-wide copy number alterations and differential gene expression in different types of North-Indian pediatric brain tumors](#). *Gene* **576**(2, Pt 2): 734–742 (2016).
- Küstters-Vandeveld, H. V. N., et al. [Mutations in G Protein Encoding Genes and Chromosomal Alterations in Primary Leptomeningeal Melanocytic Neoplasms](#). *Pathology & Oncology Research* **21**(2): 439–447 (2015).
- Paxton C. N., Rowe L. R., South S. T. [Observations of the genomic landscape beyond 1p19q deletions and EGFR amplification in glioma](#). *Molecular Cytogenetics* **8**:60 (2015).
- Nakae S., et al. [PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas](#). *PLoS ONE* **10**(11): e0142750 (2015).
- Li X., et al. [Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma](#). *Oncogene* **34**:1619–1628 (2015).

Breast

- Huw L-Y., et al. [Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer](#). *Oncogenesis* **2**:e83 (2013).
- Zhang L., et al. [Bayesian hierarchical structured variable selection methods with application to molecular inversion probe studies in breast cancer](#). *Journal of the Royal Statistical Society: Series C (Applied Statistics)* **63**(4):595–620 (2014).
- Muller K. E., et al. [Benign phyllodes tumor of the breast recurring as a malignant phyllodes tumor and spindle cell metaplastic carcinoma](#). *Human Pathology* **46**(2):327–333 (2015).

- Hagelstrom R. T., et al. [Breast Cancer and Non-Hodgkin Lymphoma in a Young Male with Cowden Syndrome](#). *Pediatric Blood & Cancer* **63**(3):544–546 (2016).
- Tan W. J., et al. [CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival](#). *Modern Pathology* **28**:352–358 (2015).
- Chen K., et al. [Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors](#). *Clinical Chemistry* **61**(3):544–553 (2015).
- Gorringe K. L., et al. [Copy number analysis of ductal carcinoma in situ with and without recurrence](#). *Modern Pathology* **28**:1174–1184 (2015).
- Liu Y., et al. [Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer](#). *Breast Cancer Research and Treatment* **143**(1):189–201 (2014).
- Manié E., et al. [Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas](#). *International Journal of Cancer* **138**(4):891–900 (2016).
- Valdez K. E., et al. [Human primary ductal carcinoma in situ \(DCIS\) subtype-specific pathology is preserved in a mouse intraductal \(MIND\) xenograft model](#). *Journal of Pathology* **225**(4):565–573 (2011).
- Johnson C. E., et al. [Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma](#). *Breast Cancer Research and Treatment* **133**(3):889–898 (2012).
- Thompson P.A., et al. [Loss of LRIG1 Locus Increases Risk of Early and Late Relapse of Stage I/II Breast Cancer](#). *Cancer Research* **74**(11):2928–2935 (2014).
- Takano E. A., et al. [Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous](#). *Journal of Clinical Pathology* **68**:362–367 (2015).
- Bousamra A., et al. [Molecular Inversion Probe Technology Generates High-Quality HER2 Copy Number Data in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissue](#). *Journal of Cancer & Clinical Oncology* **1**(1) (2015).
- Tan W. J., et al. [Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups](#). *Breast Cancer Research Treatment* **145**(3):635–645 (2014).
- Bidard F. C., et al. [Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer](#). *Annals of Oncology* **26**(8):1704–1709 (2015).
- Schouten P. C., et al. [Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms](#). *Molecular Oncology* **9**(7):1274–1286 (2015).

Burkitt Lymphoma

- Schiffman J. D., et al. [Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression](#). *British Journal of Haematology* **155**(4):477–486 (2011).
- Leventaki V., et al. [TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases](#). *British Journal of Haematology* **158**(6):763–771 (2012).

Central Nervous System

- Gessi M., et al. [H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system \(CNS-PNET\) and pediatric glioblastomas: possible diagnostic and therapeutic implications?](#) *Journal of Neuro-Oncology* **112**(1):67–72 (2013).
- Gessi, M., et al. [High-Resolution Genomic Analysis of Cribriform Neuroepithelial Tumors of the Central Nervous System](#). *Journal of Neuropathology & Experimental Neurology* **74**(10):970–974 (2015).
- Gessi M., et al. [MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system](#). *Neuro-Oncology* **16**(7):924–932 (2014).

Colon/Colorectal

Xie T., et al. [A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations.](#) *PLoS One* **7**(7):e42001 (2012).

Bellido F., et al. [Comprehensive molecular characterisation of hereditary non-polyposis colorectal tumours with mismatch repair proficiency](#) *European Journal of Cancer* **50**(11):1964–1972 (2014).

de Voer R. M., et al. [Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer](#) *Scientific Report* **5**:14060 (2015).

Richman S. D., et al. [HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials](#) *The Journal of Pathology* **238**(4):562–570 (2016).

Hardiman K. M., et al. [Intra-tumor genetic heterogeneity in rectal cancer](#) *Laboratory Investigation* **96**:4–15 (2016).

Beggs A. D., et al. [Loss of Expression and Promoter Methylation of SLIT2 Are Associated with Sessile Serrated Adenoma Formation](#) *PLoS Genetics* **9**(5) e1003488 (2013).

Kopetz S., et al. [Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer](#) *Journal of Clinical Oncology* (2015). doi:10.1200/JCO.2015.63.2497

Mao M., et al. [Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents](#) *Clinical Cancer Research* **19**(3):657–667 (2013).

Gastrointestinal

Belinsky M. G., et al. [Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.](#) *Genes, Chromosomes and Cancer* **52**(2):214–224 (2013).

Germ Cell Tumors

Subbiah V., et al. [Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib \(Sutent®\) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial](#) *Journal of Hematology & Oncology* **7**:52 (2014).

Kidney

Hasselblatt M., et al. [High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.](#) *Genes Chromosomes Cancer* **52**(2):185–190 (2013).

Langerhans Cells

Karai, L. J., et al. [Langerhans Cell Sarcoma With Lineage Infidelity/Plasticity: A Diagnostic Challenge and Insight Into the Pathobiology of the Disease](#) *American Journal of Dermatopathology* **37**(11):854–861 (2015).

Liver

Shastri A., et al. [Primary Hepatic Small Cell Carcinoma: Two Case Reports, Molecular Characterization and Pooled Analysis of Known Clinical Data](#) *Anticancer Research* **36**(1):271–277 (2016).

Lung

Jedrzkiwicz J., et al. [Congenital peribronchial myofibroblastic tumor: Case report and review of literature](#) *Journal of Pediatric Surgery Case Reports* **3**(4):154–157 (2015).

Araujo L. H., et al. [Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing](#) *Journal of Clinical Oncology* **33**(17):1966–1973 (2015).

Lymphoid Tissue/Lymphoma

Salaverria I., et al. [High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas](#). *Genes Chromosomes Cancer* **52**(2):150–155 (2013).

Sebastián E., et al. [High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma](#). *Annals of Hematology* **95**(2):253–262 (2016).

Waanders E., et al. [Independent development of lymphoid and histiocytic malignancies from a shared early precursor](#). *Leukemia* **30**(4):955–958 (2016).

Yoon H., et al. [Integrated copy number and gene expression profiling analysis of epstein–barr virus-positive diffuse large b-cell lymphoma](#). *Genes, Chromosomes and Cancer* **54**(6):383–396 (2015).

Martin-Guerrero I., et al. [Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas](#). *Haematologia* **98**:1237–1241 (2013).

Melanoma

Wang L., et al. [Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP-array and next generation sequencing analysis](#) *Genes, Chromosomes and Cancer* **54**(8):463–471 (2015).

Chandler W. M., et al. [Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements](#). *Archives of Pathology & Laboratory Medicine* **136**(8):947–955 (2012).

Chan M. P., et al. [Genomic copy number analysis of a spectrum of blue nevi identifies recurrent aberrations of entire chromosomal arms in melanoma ex blue nevus](#) *Modern Pathology* **29**:227–239 (2016).

Anaka M., et al. [Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors](#). *BMC Medical Genomics* **6**:40 (2013).

Harris K., et al. [Melanoma mimic: a case of multiple pagetoid Spitz nevi](#). *Archives of Dermatology* **148**:370–374 (2012).

Nguyen, T. L. T., et al. [Mitotically Active Proliferative Nodule Arising in a Giant Congenital Melanocytic Nevus: A Diagnostic Pitfall](#). *American Journal of Dermatopathology* **35**(1):e16–e21 (2013).

Gandolfi G., et al. [The extent of whole-genome copy number alterations predicts aggressive features in primary melanomas](#). *Pigment Cell & Melanoma Research* **29**(2):163–175 (2016).

Lu C., et al. [The Genomic Landscape of Childhood and Adolescent Melanoma](#) *Journal of Investigative Dermatology* **135**(3):816–823 (2015).

van Engen-van Grunsven, A. C. H., et al. [Whole-genome copy-number analysis identifies new leads for chromosomal aberrations involved in the oncogenesis and metastatic behavior of uveal melanomas](#). *Melanoma Research* **25**(3):200–209 (2015).

Mesothelioma

Cheung M., et al. [An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation](#). *Cancer Genetics* **208**(10):502–507 (2015).

Cheung M., et al. [Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene–environment interaction](#). *Cancer Letters* **369**(2):261–265 (2015).

Neuroblastoma

Pinto N., et al. [Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence](#). *Pediatric Blood & Cancer* **63**(6):1019–1023 (2016).

Ovary

Hunter S. M., et al. [Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?](#) *Clinical Cancer Research* **17**:7273–7282 (2011).

Geiersbach K. B., et al. [FOXL2 mutation and large-scale genomic imbalances in adult granulosa cell tumors of the ovary.](#) *Cancer Genetics* **204**(11):596–602 (2011).

Skirnisdottir I., et al. [Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.](#) *BMC Cancer* **12**(1):407 (2012).

Lavrut P-M., et al. [Small cell carcinoma of the ovary, hypercalcemic type/ ovarian malignant rhabdoid tumor: report of a bilateral case in a teenager associated with SMARCA4 germline mutation.](#) *Pediatric and Developmental Pathology* **19**(1):56–60 (2016).

Pineal Tumors

Heim S., et al. [Papillary tumor of the pineal region: A distinct molecular entity.](#) *Brain Pathology* **26**(2):199–205 (2016).

Goschzik T., et al. [PTEN Mutations and Activation of the PI3K/Akt/mTOR Signaling Pathway in Papillary Tumors of the Pineal Region.](#) *Journal of Neuropathology & Experimental Neurology* **73**(8):747–751 (2014).

Prostate

Pearlman A., et al. [Clustering-Based Method for Developing a Genomic Copy Number Alteration Signature for Predicting the Metastatic Potential of Prostate Cancer.](#) *Journal of Probability and Statistics* **2012**:873570 (2012). *OncoScan® FFPE Assay Kit not mentioned in article; authors acknowledge using OncoScan® FFPE Assay Kit in BioArray News, 23 Oct 2012*

Aparicio A. M., et al. [Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.](#) *Clinical Cancer Research* **22**(6):1520–1530 (2016).

Risbridger G. P., et al. [Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor Prognosis.](#) *European Urology* **67**(3):496–503 (2015).

Boutros P.C., et al. [Spatial genomic heterogeneity within localized, multifocal prostate cancer.](#) *Nature Genetics* **47**:736–745 (2015).

Renal/Kidney

Calderaro J., et al. [Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.](#) *European Urology* **69**(6):1055–1061 (2016).

Alexiev B. A., Ying S. Zou Y. S. [Clear cell papillary renal cell carcinoma: A chromosomal microarray analysis of two cases using a novel Molecular Inversion Probe \(MIP\) technology.](#) *Pathology - Research and Practice* **210**(12):1049-1053 (2014).

Trpkov K., et al. [Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women.](#) *American Journal of Surgical Pathology* **4**(1):60–71 (2016).

Singh N., et al. [Retrospective analysis of FFPE based Wilms' Tumor samples through Copy Number and Somatic Mutation related Molecular Inversion Probe Based Array.](#) *Gene* **565**(2): 295–308 (2015).

Skeletal Muscle/Rhabdomyosarcoma

Kohsaka S., et al. [A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.](#) *Nature Genetics* **46**:595–600 (2014).

Skin

Harms P. W., et al. [Cutaneous basal cell carcinomas: evidence of clonality and recurrent chromosomal losses](#). *Human Pathology* **46**(5):690–697 (2015).

Verneuil L., et al. [Human skin carcinoma arising from kidney transplant-derived tumor cells](#). *Journal of Clinical Investigation* **123**(9):3797–3801 (2013).

Spleen

Xu L., et al. [Well-differentiated angiosarcoma of spleen: a teaching case mimicking hemangioma and cytogenetic analysis with array comparative genomic hybridization](#). *World Journal of Surgical Oncology* **13**:300 (2015).

Squamous Cell Carcinoma

Lee C. S., et al. [Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma](#). *Nature Genetics* **46**:1060–1062 (2014).

Synovial Sarcoma

Vlenterie M., et al. [Next generation sequencing in synovial sarcoma reveals novel gene mutations](#). *Oncotarget* **6**(33):34680–34690 (2015).

Thoracic Neoplasms

Le Loarer F., et al. [SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas](#). *Nature Genetics* **47**:1200–1205 (2015).

Uterus/Endometrial

Hunter S. M., et al. [Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas](#). *The American Journal of Pathology* **184**(6):1871–1876 (2014).

Chao A., et al. [Molecular characteristics of endometrial cancer coexisting with peritoneal malignant mesothelioma in Li-Fraumeni-like syndrome](#). *BMC Cancer* **15**:8 (2015).

Holzmann C., et al. [Patterns of Chromosomal Abnormalities that Can Improve Diagnosis of Uterine Smooth Muscle Tumors](#). *Anticancer Research* **35**(12):6445–6456 (2015).

Methods

Krijgsman O., et al. [CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material](#). *Genes, Chromosomes and Cancer* **51**(4):344–352 (2012).

Singh R. R., et al. [Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumors](#). *British Journal of Cancer* **111**:2014–2023 (2014).

Hubaux R., et al. [Comparative Genomic Hybridization and Array Based CGH in Cancer](#) [chapter 3] in *Molecular Testing in Cancer*, eds. G. M. Yousef, S. Jothy (New York: Springer), 27–37 (2014).

Foster J. M., et al. [Cross-laboratory validation of the OncoScan® FFPE Assay, a multiplex tool for whole genome tumour profiling](#). *BMC Medical Genomic* **8**:5 (2015).

Hosein A. N., et al. [Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis](#). *Laboratory Investigation* **93**:701–710 (2013).

Shen R., Seshan V. [FACETS: Fraction and Allele-Specific Copy Number Estimates from Tumor Sequencing](#). *Memorial Sloan-Kettering Cancer Center, Dept. of Epidemiology & Biostatistics Working Paper Series. Working Paper 29* (n.d.).

Mirza M. K., et al. [Genomic Aberrations in Myeloid Sarcoma without Blood or Bone Marrow Involvement: Characterization of Formalin-Fixed Paraffin-Embedded Samples by Chromosomal Microarrays](#). *Leukemia Research* **38**(9):1091–1096 (2014).

Piqueret-Stephan L., et al. [Massively parallel DNA sequencing from routinely processed cytological smears](#). *Cancer Cytopathology* **124**(4):241–253 (2016).

Gentien D., Reyes C. [Microarrays-Based Molecular Profiling to Identify Genomic Alterations](#) [chapter 4] in *Pan-Cancer Integrative Molecular Portrait Towards a New Paradigm in Precision Medicine*, eds. C. Le Tourneau, M. Kamal (Switzerland: Springer), 31–45 (2015).

Albertson D. G. [Molecular Genetics Methods in Discovery of Chromosome Structure](#) [chapter 2] in *Chromosomal Translocations and Genome Rearrangements in Cancer*, eds. J. D. Rowley, M. M. Le Beau, T. H. Rabbitts (Switzerland: Springer), 15–25 (2015).

Busacca S., et al. [Resistance to HSP90 inhibition involving loss of MCL1 addiction](#). *Oncogene* **35**:1483–1492 (2016).

Chong L. C., et al. [SeqControl: process control for DNA sequencing](#). *Nature Methods* **11**:1071–1075 (2014).

Elizabeth C. Chastain, E. C. [Targeted Hybrid Capture Methods](#) [chapter 3], in *Clinical Genomics*, ed. S. Kulkarni, et al. (Amsterdam: Academic Press), 37–55 (2015).

Birkbak N. J., et al. [Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents](#). *Cancer Discovery* **2**:366 (2012).

Park J. H., et al. [Universal probe amplification: Multiplex screening technologies for genetic variations](#). *Biotechnology Journal [special issue: Biotech Methods and Advances]* **10**(1):45–55 (2015).

Zahir F. R., Marra M. A. [Use of Affymetrix Arrays in the Diagnosis of Gene Copy-Number Variation](#) *Current Protocols in Human Genetics* **Unit 8.13** (2015).

Reviews

Hasty P., Montagna C. [Chromosomal rearrangements in cancer: detection and potential causal mechanisms](#). *Molecular & Cellular Oncology* **1**(1):e29904 (2014).

Rode A., et al. [Chromothripsis in cancer cells: an update](#). *International Journal of Cancer* (10):2322–2333 (2016).

Wang Y., Cottman M., Schiffman J. D., [Molecular inversion probes: a novel microarray technology and its application in cancer research](#). *Cancer Genetics* **205**(7-8):341–355 (2012).

Gray P. N., Dunlop C. L. M, M. Elliott A. M. [Not all next generation sequencing diagnostics are created equal: understanding the nuances of solid tumor assay design for somatic mutation detection](#). *Cancers* **7**(3):1313–1332 (2015).

Affymetrix, Inc: (US) +1-888-362-2447, +1-408-731-5000 ■ (EU) +44-(0)1628-552550 ■ (JP) +81-(0)3-6430-4020 ■ (CN) +86-21-63915511
eBioscience Products: (US) +1-888-999-1371, +1-858-642-2058 ■ (EU) +43 1 796 40 40 305 ■ (JP) +81-(0)3-6430-4020
USB Products: (US) +1-800-321-9322, +1-216-765-5000 ■ (EU) +44-(0)1628-552600

www.affymetrix.com Please visit our website for international distributor contact information.

For Research Use Only. Not for use in diagnostic procedures.

P/N GCL07420 Rev. 1

© 2016 Affymetrix, Inc. All rights reserved. Please see affymetrix.com/trademarks for a complete list of Affymetrix trademarks. All other trademarks are the property of their respective owners.